参考文献/References:
[1] Teare D. Asymmetrical hypertrophy of the heart in young adults[J]. Br Heart J,1958,20(1):1-8. [2] Ullal AJ,Abdelfattah RS,Ashley EA,et al. Hypertrophic cardiomyopathy as a cause of?udden cardiac death in the young: a meta-analysis[J]. Am J Med,2016,129(5):486-496.e2. [3] Rath A,Weintraub R.Overview of cardiomyopathies in childhood[J]. Front Pediatr,2021,9:708732. [4] Yetman AT,Hamilton RM,Benson LN,et al. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,1998,32(7):1943-1950. [5] 张艳敏,李自普,韩玲,等.中国儿童肥厚型心肌病诊断的专家共识[J].中国实用儿科杂志,2019,34(5):329-334.[6] 张红菊,徐丽媛,靳璟,等.儿童肥厚型心肌病的超声心动图及临床特征分析[J].心肺血管病杂志,2022,41(5):537-542.[7] Colan SD,Lipshultz SE,Lowe AM,et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children:findings from the Pediatric Cardiomyopathy Registry[J]. Circulation,2007,115(6):773-781. [8] Norrish G,Field E,Mcleod K,et al. Clinical presentation and survival of childhood hypertrophic cardiomyopathy:a retrospective study in United Kingdom[J]. Eur Heart J,2019,40(12):986-993.[9] 谭鎣,吕铁伟.儿童肥厚型心肌病的磁共振与CT检查[J].中国实用儿科杂志,2019,34(5):357-362.[10] Gersh BJ,Maron BJ,Bonow RO,et al.2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation,2011,124:e783-e831.[11] Elliott PM,Anastasakis A,Borger MA,et al.2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) [J].Eur Heart J,2014,35(39):2733-2779.[12] 张乾忠,马沛然,陈新民,等.小儿心肌病诊治进展[J].中国实用儿科杂志,2006,21(2):81-92.[13] O’Mahony C,Jichi F,Pavlou M,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)[J].?ur Heart J,2014,35(30):2010-2020.[14] Bharucha T,Lee KJ,Daubeney PE,et al. Sudden death in childhood cardiomyopathy: results from a long-term national population-based study[J].? Am Coll Cardiol,2015,65(21):2302-2310.?15] Decker JA,Rossano JW,Smith EO,et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children[J]. J Am Coll Cardiol,2009,54(3):250-254. [16] Guttmann OP,Rahman MS,O’mahony C,et al.Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:systematic review[J].Heart,2014,100(6):465-472.[17]丁文虹,韩玲,刘炘翰.儿童肥厚型心肌病的超声学检查[J].中国实用儿科杂志,2019,34(5):352-356.[18] 徐顺芯,孔伟星.磁共振成像与超声心动图对儿童肥厚型心肌病的诊断分析研究[J].全科医学临床与教育,2020,18(4):314-317.[19] Sado DM,White SK,Piechnik SK,et al.Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping[J].Circ Cardiovasc Imaging,2013,6(3):392-398.[20] 闫朝武,方纬,汪蕾.儿童肥厚型心肌病磁共振延迟强化特征分析[J].国际放射医学核医学杂志,2018,42(3):233-236+256.[21] Bruder O,Wagner A,Jensen CJ,et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2010,56(11):875-887. [22] 沈亦时,傅国胜,孙雅逊.肥厚型心肌病的诊疗进展[J].临床心电学杂志,2018,27(1):49-54.[23] Ostman-Smith I,Wettrell G,Keeton B,et al. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly[J]. Cardiol Young,2005,15(6):632-642.[24] 张海燕,许静.儿童肥厚型心肌病心室复极功能改变及临床应用价值[J].中国妇幼健康研究,2022,33(6):108-111.[25] Arteyeva NV. Dispersion of ventricular repolarization:temporal and spatial[J].World J Cardiol,2020,12(9):437-449.[26] Nakano SJ,Menon SC. Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap[J]? Prog Pediatr Cardiol,2018,49:31-37. [27] Kalisz K,Rajiah P. Computed tomography of cardiomyopathies[J]. Cardiovasc Diagn Ther,2017,7(5):539-556. [28] 马晓海,赵蕾,葛海龙,等.延迟增强CT评估肥厚型心肌病心肌纤维化的意义[J].中国医学影像学杂志,2015,23(2):100-104.[29] 王箭.延迟增强CT评估肥厚型心肌病心肌纤维化的意义[J].中西医结合心血管病电子杂志,2019,7(31):84.[30] 中华医学会心血管病学分会中国成人肥厚型心肌病诊断与治疗指南编写组,《中华心血管病杂志》编辑委员会.中国成人肥厚型心肌病诊断与治疗指南[J].中华心血管病杂志,2017,45(12):1015-1032.[31] 郭颖,高伟,傅立军,等.有创性心导管检查对限制性心肌病和缩窄性心包炎的诊断价值[J].中华实用儿科临床杂志,2017,32(1):34-37.[32] Kang E,Kim YM,Kang M,et al.Clinical and genetic characteristics of patients with fatty acid oxidation disorders identified by newborn screening[J].BMC Pediatr,2018,18(1):103.[33] Geisterfer-Lowrance AA,Kass S,Tanigawa G,et al.A molecular basis for familial hypertrophic cardiomyopathy:a beta cardiac myosin heavy chain gene missense mutation[J].Cell,1990,62(5):999-1006.[34] Moak JP,Kaski JP. Hypertrophic cardiomyopathy in children[J]. Heart,2012,98(14):1044-1054. [35] Chan W,Yang S,Wang J,et al. Clinical characteristics and survival of children with hyp-ertrophic cardiomyopathyin China:a multicentre retrospective cohort study[J].?ClinicalMedicine,2022,49:101466.[36] Nishimura RA,Holmes DR Jr.Clinical practice.Hypertrophic obstructive cardiomyopathy[J].N Engl J Med,2004,350(13):1320-1327.[37] Walsh R,Thomson KL,Ware JS,et al.Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706reference samples[J].Genet Med,2017,19 (2):192-203.[38] García-Giustiniani D,Arad M,Ortíz-Genga M,et al. Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain[J].?eart,2015,101(13):1047-1053.?39] Mori AA,Castro LR,Bortolin RH,et al. Association of variants in MYH7,MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy[J].?orensic Sci Int Genet,2021,52:102478.[40] Miron A,Lafreniere-Roula M,Steve Fan CP,et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy[J].?irculation,2020,142(3):217-229.?/html>
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(8):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(8):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[3]刘颖,袁美锦.儿童与青少年心脏性猝死的病因和预防[J].心血管病学进展,2019,(6):935.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.024]
LIU Ying,YUAN Meijin.Causes and Prevention of Sudden Cardiac Death in Children and Adolescents[J].Advances in Cardiovascular Diseases,2019,(8):935.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.024]
[4]马佳 陈肯 张宇清.儿童及青少年单纯收缩期高血压发病机制研究进展[J].心血管病学进展,2020,(4):392.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.016]
MA Jia,CHEN Ken,ZHANG Yuqing.The Pathogenesis of Isolated Systolic Hypertension in Children and Adolescents[J].Advances in Cardiovascular Diseases,2020,(8):392.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.016]
[5]石树文 田雯.肠道微生物群与儿童川崎病[J].心血管病学进展,2020,(6):608.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.012]
SHI ShuwenTIAN Wen. Intestinal microbiota and children Kawasaki disease[J].Advances in Cardiovascular Diseases,2020,(8):608.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.012]
[6]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(8):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[7]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[8]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(8):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[9]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(8):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[10]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(8):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]